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Abstract
Parkinson disease (PD) is a complex neurodegenerative disorder with largely unknown genetic mechanisms. While the
degeneration of dopaminergic neurons in PD mainly takes place in the substantia nigra pars compacta (SN) region, other
brain areas, including the prefrontal cortex, develop Lewy bodies, the neuropathological hallmark of PD. We generated and
analyzed expression data from the prefrontal cortex Brodmann Area 9 (BA9) of 27 PD and 26 control samples using the 44K
One-Color Agilent 60-mer Whole Human Genome Microarray. All samples were male, without significant Alzheimer disease
pathology and with extensive pathological annotation available. 507 of the 39,122 analyzed expression probes were
different between PD and control samples at false discovery rate (FDR) of 5%. One of the genes with significantly increased
expression in PD was the forkhead box O1 (FOXO1) transcription factor. Notably, genes carrying the FoxO1 binding site were
significantly enriched in the FDR–significant group of genes (177 genes covered by 189 probes), suggesting a role for FoxO1
upstream of the observed expression changes. Single-nucleotide polymorphisms (SNPs) selected from a recent meta-
analysis of PD genome-wide association studies (GWAS) were successfully genotyped in 50 out of the 53 microarray brains,
allowing a targeted expression–SNP (eSNP) analysis for 52 SNPs associated with PD affection at genome-wide significance
and the 189 probes from FoxO1 regulated genes. A significant association was observed between a SNP in the cyclin G
associated kinase (GAK) gene and a probe in the spermine oxidase (SMOX) gene. Further examination of the FOXO1 region in
a meta-analysis of six available GWAS showed two SNPs significantly associated with age at onset of PD. These results
implicate FOXO1 as a PD–relevant gene and warrant further functional analyses of its transcriptional regulatory mechanisms.
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Introduction
Parkinson disease (PD, OMIM #168600) is a neurodegenera-
tive disorder, which affects primarily motor function (difficulty in
movement initiation, tremor, slowness of movement), and
secondarily cognitive capabilities of affected individuals. The
lifetime risk for the disease is 1.5%, with a median age at onset of
60 and 1.5 increased risk in men compared to women. While a
minority of PD cases has been attributed to rare monogenic forms,
most cases are likely to be attributed to both genetic and
environmental influences [1]. PD has an established pathology,
with depletion of up to 60% of dopaminergic neurons in the
substantia nigra pars compacta (SN) brain region prior to the onset of
motor symptoms, and with protein inclusion aggregates known as
Lewy bodies. Nevertheless, the specific cellular mechanisms
involved in the onset and propagation of PD are still largely
undetermined [2].
A common strategy for studying neurodegenerative diseases has
been the analysis of gene expression differences between diseased
and neurologically healthy control brain samples using microarray
PLoS Genetics | www.plosgenetics.org 1 June 2012 | Volume 8 | Issue 6 | e1002794technologies. Given its strong pathology in PD, the region of
choice for assessing disease-specific expression changes has been
SN. Whole SN tissue samples, as well as individually captured
dopaminergic neurons from this brain region, have been used in
prior microarray studies [3]. Nonetheless, the significant loss of
dopaminergic neurons and the likely reactive responses present in
surviving neurons at the time of patient death make the
interpretation of expression data from SN challenging. The
Sutherland et al. study [4] compared results from multiple SN
PD microarrays and found low concordance among the implicated
genes and pathways. Possible reasons for the inconsistent results
might have been the small sample sizes used in individual
experiments, the pronounced loss of pigmented SN neurons in PD
cases, other types of cellular heterogeneity within and between
disease and control specimens, and the large variability attribut-
able to gender, age, RNA quality, post-mortem interval, and co-
occurrence of other neurological disorders (e.g. Alzheimer disease
pathology). Recently, the Zheng et al. study [3] used a gene-set
enrichment meta-analysis approach to analyze expression data
from a total of 17 studies (mostly SN, but also studies from other
brain regions, as well as blood and human lymphoblastoid cells).
They found 10 gene sets to be consistently associated with PD,
including the gene set corresponding to 425 PGC-1a-responsive
nuclear-encoded mitochondrial genes. Given this result and
additional expression results from cellular disease models, the
authors concluded that PGC-1a (PPARGC1A, peroxisome prolif-
erator-activated receptor gamma, coactivator 1 alpha, Entrez
ID=10891) is implicated in PD and is a potential therapeutic
target for the disease. Additionally, strategies for the integration of
different types of data sources for the study of PD have emerged; a
recent study by Edwards et al. (2011) combined expression and
GWAS data from non-overlapping samples to detect biological
pathways that might be relevant for PD [5].
In the current study, we sought to analyze expression differences
between PD and neurologically healthy controls in a manner that
would maximize our control of possible technical and design
confounders, to the extent possible for a tissue homogenate
microarray study. Using the One-Color Agilent 60-mer Whole
Human Genome Microarray, we investigated expression differ-
ences in the prefrontal cortex Brodmann Area 9 (BA9) in the
largest PD brain study to date (27 PD and 26 control samples, E-
MTAB-812 ArrayExpress dataset). For the microarray experiment
we used prefrontal cortex, a brain region which contains
dopaminergic neuron projections, does not show the pronounced
cell death observed in SN, while still being molecularly and
pathologically affected by the disease [2,6,7]. The samples
included in our study were highly homogenous: all were from
males, with high pH values, and none showed significant
Alzheimer disease pathology (e.g. the sample is that of pure Lewy
body pathology for cases). To our knowledge, this sample is the
most homogenous ever studied for PD (Table 1, Table S1). In
addition to our microarray expression data, we had genotyping
data available for 50 of the 53 samples, consisting of all 56
genome-wide significant SNPs derived from the US-PD GWAS
consortium meta-analysis [8]. We combined the 52 genome-wide
significant SNPs with minor allele frequencies greater than 0.1
with 189 microarray probes with false discovery rate (FDR) less
than 0.05 and located in genes with common FoxO1 regulation in
a targeted expression-SNP (eSNP) study. The performed analyses
implicate the forkhead box O1 (FOXO1) gene as having an
important regulatory role for PD. Furthermore, support for
FOXO1 was found in its association to age at onset (AAO) in the
US PD-GWAS consortium data [8].
Results
Differential expression analysis for 27 PD and 26 control
prefrontal cortex samples (see Materials and Methods, Microarray
QC and differential expression analysis section) revealed 507
mRNA probes, within 489 expressed regions (known genes, as well
as non-genic expressed genomic elements), with FDR-adjusted
p,0.05. Among these differentially expressed probes, 50 had fold
changes greater than 1.5. These 50 probes are displayed in
Figure 1 and all the FDR significant probes are presented in Table
S2. Since three of the available microarray samples had RIN
values below 6, we performed a secondary differential expression
analysis after removal of these samples [9]. The obtained FDR-
significant results, consisting of 912 mRNA probes, are displayed
in Table S5. The 36 probes that reached FDR-level of significance
when the entire set of brains was used, but not after removal of low
RIN samples are indicated in Table S2. Notably, the fold changes
between PD and control samples were generally small, with few
probes having fold changes larger than 2. This result differs from
some of the previously published SN studies, where the contrasts
between the two groups displayed large fold changes [10,11],
which may be attributable to artifacts introduced in the study of
SN.
Functional analyses for the FDR-significant genes that were
present in the Database for Annotation, Visualization and
Integrated Discovery (DAVID) v6.7 and in Ingenuity’s Pathway
Analysis software (IPA) were performed. 418 of the 507 FDR-
significant probes (82.4%) were mapped to 395 genes present in
DAVID’s database. None of the gene ontology (GO) terms present
in DAVID reached Bonferroni or FDR-adjusted statistical
significance at a=0.05 for this set of genes. Nevertheless, brain-
specific GO terms with nominal enrichment were observed, such
as ‘‘neuron development’’, ‘‘neuron projection development’’,
‘‘gliogenesis’’, and ‘‘neuron differentiation’’. The DAVID analysis
showed ten transcription factor-binding sites (TFBS) enriched at a
Bonferroni level of significance less than 0.001 and with a fold
enrichment of at least 1.2 for the mapped FDR-significant genes.
The fold enrichment represents the ratio between the percentage
of genes in the mapped gene list with a specific TFBS and the
percentage of genes in the entire DAVID database with the
Author Summary
Parkinson disease (PD) is a neurodegenerative disease,
which impairs the motor and cognitive abilities of affected
individuals. Although the involvement of specific genes in
the disease process has been recognized, the underlying
genetic mechanisms are not yet understood. One common
investigation approach for PD has been the comparison of
gene expression levels in brain tissue from PD cases with
those from neurologically healthy controls. We performed
such an expression analysis in prefrontal cortex tissue from
a set of 27 PD and 26 control samples. One of the 489
differentially expressed genes, forkhead box O1 (FOXO1), is
involved in transcriptional regulation. Notably, the set of
differentially expressed genes identified in our study was
enriched for genes regulated by the FoxO1 protein.
Analyses of DNA sequence variants known as single-
nucleotide polymorphisms (SNPs) in the FOXO1 region, as
well as of PD–relevant SNPs across the genome, suggest
functional connections between this gene and 1) the age
at onset in PD, and 2) the spermine oxidase (SMOX) gene.
These findings implicate the involvement of FOXO1 in PD
pathogenesis.
FOXO1 Transcriptional Regulation in PD
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(Bonferroni p=1.3E-4, fold enrichment=1.4) was the only one
that corresponded to a gene that was also differentially expressed
at FDR significance in the microarray (Table S2). 177 genes with
the FoxO1 TFBS, including FOXO1 itself, were present among the
395 DAVID mapped genes (44.8%); these genes were covered by
189 FDR-significant probes. Enrichment for the FoxO1 TFBS
among FDR significant genes continued to be observed when
limiting analysis to only the genes studied in the microarray, and
not all genes in the DAVID database (x
2 p,2.2E-16, odds
ratio=1.37). Notably, although PPARGC1A, gene implicated in
the Zheng et al. study [3], was not among the differentially
expressed genes in our microarray, this gene was determined to
protect dopaminergic neurons when deacetylated by the Sirt1
(sirtuin 1) protein in the MPTP mouse model of PD [12]; SIRT1
expression was increased in PD samples compared to controls at
an FDR-level of significance in our microarray.
The FOXO1 gene had two different, but strongly correlated
(r=0.75, p=4.8E-11) probes in the microarray, both with FDR-
significantly increased expression in the PD group. Among the
Table 1. Description of retained brain samples for the Agilent microarray study.
Sample Type (n) Age at death, years (range) PMI
1, hours (range) RIN
2 (range) Tissue pH
3 (range)
Control (26) 75.03 (58–97) 13.69 (1.50–39.67) 7.39 (4.8–8.5) 6.66 (6.29–7.32)
PD (27) 77.29 (64–94) 6.47 (1.16–30.75) 7.35 (5.6–8.4) 6.68 (6.43–7.13)
1PMI: post-mortem interval.
2RIN: RNA Integrity Number.
3The pH was measured following a previously established protocol [58].
doi:10.1371/journal.pgen.1002794.t001
Figure 1. Top microarray probes. Probes with FDR-adjusted p-values smaller than 0.05 and with expression differences between PD and control
prefrontal cortex BA9 samples greater than 1.5 fold changes. Twenty-one probes (42%) were in genes with FoxO1 transcription factor binding sites.
The GENE-E software (http://www.broadinstitute.org/cancer/software/GENE-E/) was used to generate the heatmap.
doi:10.1371/journal.pgen.1002794.g001
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TFBS (and excluding the two FOXO1 probes), 78.07% were also
associated with an increase in expression for the PD group
compared with the control group. This percentage is significantly
greater than that observed in the remaining 318 FDR significant
probes, where only 66.35% were associated with increased
expression in the PD group (x
2=7.81; p=0.0052).
We used Ingenuity’s IPA software to identify functional
categories enriched for significantly associated genes and to build
a functional network based on identified categories related to
neurological diseases and processes. The network was constructed
by starting with 412 unique genes with at least one FDR significant
probe, and that were included in the IPA database. The genes
present in two of the top nominally enriched functional categories,
‘‘Nervous System Development and Function’’ (individual func-
tions annotation p-values between 2.56E-4 and 2.39E-2) and
‘‘Neurological Disease’’ (individual functions annotation p-values
between 5.68E-4 and 2.39E-2), were merged to form a custom
network. The FOXO1 gene was added to this network, and the
largest connected component of the network was retained (Figure
S1). Among the 31 genes included in this merger of neurologically
relevant functional categories (without FOXO1), 24 genes with
FoxO1 sites were present (77.4%), which is significantly more than
the 44.8% observed in all FDR-significant genes.
To validate our microarray results, we used the QuantiGene
Plex 2.0 gene expression assay (Affymetrix, Santa Clara, CA, see
Materials and Methods, Microarray validation experiment section)
for a subset of 8 PD and 9 control samples included in the
microarray. We analyzed the expression of 10 genes that
contained probes with FDR significance in the microarray. A
microarray gene was validated if the fold change obtained for the
analysis of the QuantiGene expression data was in the same
direction as the fold change obtained for the analysis of the
microarray data in the same subset of 17 samples. By this criterion,
nine out of the ten considered genes, including FOXO1, were
validated (Table S3). The difference in expression of FOXO1 was
nominally significant for the validation study.
We compared our results with those obtained using the
Affymetrix HG-U133A microarray data published by Zhang et
al. [11], which was the only prior PD microarray performed in
prefrontal cortex BA9 tissue. With 27 out of the 11,191 genes
present on both microarray platforms showing consistent expres-
sion dysregulation, we could not detect a significant overlap
between the top genes identified by the two BA9 studies (x
2 test
p=0.61, see Materials and Methods, Analysis of prior PD
prefrontal cortex and substantia nigra microarray studies section).
The top genes were defined as the set of genes with FDR adjusted
p-values below 0.05 for our Agilent microarray (278 out of the
11,191 genes), and the set of genes with unadjusted p-values
smaller than 0.05 for the Affymetrix microarray (1,012 out of the
11,191 genes). Despite the lack of significant overlap between the
two studies, FOXO1 was one of the replicated genes, showing
increased expression in PD samples in the Zhang et al. BA9 data
(probe=202723_s_at, p=0.004, FC=1.48). The FDR-significant
genes from our microarray study with positive nominal signal in
the Zhang et al. study are presented in Table S2.
To further investigate the observed enrichment for genes
containing the FoxO1 TFBS among those identified as FDR
significant microarray results, we performed a targeted eSNP
analysis in the microarray brain samples. For the eSNP analysis,
we evaluated the presence of potential regulatory effects of PD
associated SNPs on differentially expressed probes from genes with
FoxO1 TFBS (see Materials and Methods, SNP genotyping and
eSNP analysis sections). We detected a single eSNP relationship
(p=8.1E-6) that met the Bonferroni corrected p-value threshold of
5.36E-5 for the used effective number of SNPs (Figure 2). This
finding involved a PD GWAS genome-wide significant SNP,
rs11731387, present intronically in the GAK gene (cyclin G
associated kinase, Entrez ID=2580) and a probe present in the 39-
UTR of the SMOX gene (spermine oxidase, Entrez ID=54498).
The rs11731387 minor allele was associated with higher risk for
PD in the US PD-GWAS consortium meta-analysis (p=8.81E-9,
beta=0.3018, [8]) and with decreased SMOX expression.
Although stronger in the PD subgroup, the eSNP relationship
was present in both PD (p=7.47E-5, odds ratio=20.727) and
controls (p=0.037, odds ratio=20.494). SMOX probe expression
was increased in the PD group. Interestingly, SMOX is a gene
involved in the dopamine receptor signaling pathway, which is a
process that has had evidence for involvement in PD [13,14,15].
Additionally, we tried to reduce the group of FDR significant,
FoxO1 TFBS genes to a subset of genes which act as mediators for
the relationship between FOXO1 expression and disease status (see
Materials and Methods, Mediation analysis section). Twenty-nine
genes, including SMOX, showed evidence that suggested they may
act as mediators for the FOXO1 effect on PD (Table 2). Therefore,
these genes may be most relevant to the FOXO1 pathway relating
to PD, and could be important gene candidates for further
analyses of FOXO1 involvement in the disease.
Finally, we analyzed genome-wide SNP data from the US PD-
GWAS consortium meta-analysis [8] to further investigate the role
of SNPs in the FOXO1 region for PD affection or age at onset
(AAO). While no SNP in the FOXO1 region reached the required
p-value for significance of 8.68E-5 in the affection meta-analysis
(see Materials and Methods, PD affection and age at onset meta-
analysis for the FOXO1 gene region section), two SNPs in the
region reached this level of significance in the AAO meta-analysis
(Table 3). AAO data were available for most PD brains in the
microarray, so we investigated the FOXO1 probe expression – age
at onset relationship (Table S1), while adjusting for age at death,
post-mortem interval (PMI), and RNA integrity (RIN). FOXO1
expression was not significantly associated with age at onset
(A_23_P151426: p=0.46, beta=0.008; A_24_P22079: p=0.90,
beta=20.0007).
Discussion
We performed a microarray study in prefrontal cortex
Brodmann Area 9 (BA9), in a set of homogenous (male, non-
significant Alzheimer disease pathology) and high quality (high
pH, good RNA integrity) PD and control brain samples. To our
knowledge, this is the largest and most uniform microarray brain
study to date in PD, and we expect the expression data and
available covariate information to represent an invaluable resource
for the PD community (ArrayExpress E-MTAB-812 dataset).
While the microarray was not performed in the most-involved
brain region in PD, the substantia nigra pars compacta (SN), we
propose that the use of prefrontal cortex tissue, or of other brain
regions with neuropathological involvement of disease, but
reduced neuronal cell death, has the potential to overcome
limitations associated with the use of severely disease affected
tissues; this is especially the case when whole tissue homogenate
samples are considered. While the SN is almost completely
depleted of dopaminergic neurons by the time of autopsy [16],
prefrontal cortex tissue does not show such dramatic neuronal
death. Nevertheless, prefrontal cortex is very frequently neuro-
pathologically involved in PD [7] (74% of the cases investigated in
the Beach et al. study showed Lewy bodies and associated fibers in
this brain region), and shows biochemical alterations related to the
FOXO1 Transcriptional Regulation in PD
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appear later during the disease in the prefrontal cortex [16], the
study of BA9 may reveal pathogenically relevant disease changes.
This study found evidence of a significant role for the
transcription factor gene FOXO1 and genes under its transcrip-
tional regulation: (1) FOXO1 expression was significantly increased
in PD samples in our study, and (2) the top microarray results were
enriched for genes containing the FoxO1 transcription factor-
binding site. The increased FOXO1 expression in PD samples is
consistent with a previous PD BA9 microarray study reported by
Zhang et al. [11], the only prior PD expression study performed in
this brain region. The majority of prior PD microarray studies
performed in SN tissue also reported increased FOXO1 expression
and enrichment of FoxO1 TFBS genes in their top results, with
significant meta-analysis p-values for the two FOXO1 probes
present on the Affymetrix HG-U133A chip ranging from 4.1E-3
to 3.2E-4 (Table S4).
To further explore the significance of FoxO1 TFBS enrichment,
we performed a targeted eSNP study for FDR-significant
microarray probes located in genes with FoxO1 regulation and
SNPs known to be associated with PD affection at genome-wide
level of significance [8]. This analysis revealed a significant
relationship between the GAK SNP rs11731387 and probe
A_23_P102731 in the SMOX gene. The rs11731387 minor allele
was associated with both increased PD risk and decreased SMOX
expression. Given the observed increase in SMOX expression in
PD compared to control samples, we propose that elevated SMOX
expression in the brain is required as a protective mechanism
against the biochemical changes that lead to and are present in
PD, and is not a direct cause of the disease. This would explain
why a SNP that prevents sufficiently elevated SMOX expression
levels could enhance sensitivity to PD. When both the GAK SNP
and the expression of the A_23_P151426 FOXO1 probe were
included as predictors for the expression of the SMOX probe, the
magnitude of the effect for these two predictors changed only
slightly from the initial results, both of them remaining significant.
Given this evidence, we propose that FOXO1, GAK, and SMOX are
involved in a common biological pathway, with FOXO1 and GAK
independently influencing SMOX expression and, consequently,
PD risk.
Multiple sources of evidence have recently implicated the cyclin
G associated kinase (GAK) gene in PD [8,18,19,20,21,22,23],
although it has been unclear how this gene influences the disease.
The SMOX enzyme plays a role in polyamine catabolism, and it is
known to be involved in the response to drugs, stressful stimuli,
and apoptosis. High expression levels of SMOX have been found in
the brain and the polyamine catabolism system has been
implicated in psychiatric conditions [24]. Notably, the SMOX
protein is a component of the dopamine receptor signaling
pathway, where, together with the MAOA (monoamine oxidase
A), MAOB (monoamine oxidase B), and IL4I1 (interleukin 4
induced 1) proteins, it makes up the MAO complex (Ingenuity
Knowledge Base). Although inconsistently, MAOA and MAOB
have been linked to PD in several genetic studies [15,25,26,27,28],
and the dopamine receptor signaling pathway has been implicated
in the disease [13,14,15].
Further, we performed a mediation analysis to determine if the
expression of any of the FDR-significant FoxO1 TFBS genes
shows evidence to potentially act as an intermediary step for the
observed relationship between FOXO1 expression and PD case/
control status. This analysis showed the expression values of 29
genes (Table 2) to act as mediating variables. Notably, SMOX was
Figure 2. Expression by genotype relationship between the SMOX probe, A_23_P102731, and the GAK SNP, rs11731387. The box
whiskers extend to the most extreme data point, which is at most 1.5 times the interquartile range from the box. The result for the 2-degree of
freedom test was p=8.1E-6, and the eSNP relationship was stronger in PD (p=7.47E-5, beta=20.727) than in controls (p=0.037, beta=20.494). The
minor allele frequency for rs11731387 in the used brain sample was 0.15, and the odds ratio for this SNP in the additive model affection study of the
meta-GWAS was 1.35.
doi:10.1371/journal.pgen.1002794.g002
FOXO1 Transcriptional Regulation in PD
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mediated effect. This set of 29 genes is of particular interest for
future studies of FOXO1 involvement in PD.
Finally, we investigated the FOXO1 region for SNPs linked to
PD affection or PD age at onset (AAO) using imputed data from
the US PD-GWAS consortium [8]. While no SNP reached
statistical significance for affection, two SNPs from the FOXO1
region, rs4509910 and rs9532809, were significantly associated
with increased PD AAO. The association results for these two
SNPs and six additional ones with p-values,1E-3 for the AAO
analysis are displayed in Table 3. Using the SNPExpress database
[29], we tried to determine whether or not there is evidence for
any relationship between these SNPs and FOXO1 expression in
brain tissue. Only three of the SNPs in Table 3 were present in the
SNPExpress database; the two SNPs with significant AAO
association were not among them. From the three SNPs present
in the database, rs7987856 showed evidence for association with
FOXO1 expression: its minor allele was associated with increased
expression of the 39-UTR exon of the FOXO1 NM_002015
transcript (beta=98.91, p=3.5E-3). This SNP is in high LD with
the top AAO SNP, rs4509910, with an R
2 of 0.76 in the release 22
of the HapMap CEU population, as determined in Haploview
[30]. This result might be indicative of the existence of alternative
FOXO1 transcripts in the brain, which could have an effect on the
progression of PD.
The Forkhead box, subgroup O (FOXO) transcription factors
have been implicated recently in studies of known PD genes and
aspects of PD neurodegeneration. The FOXO3a protein was
determined to control PINK1 (PTEN induced putative kinase 1,
Entrez ID=65018) transcription in mouse and human cells
subjected to growth factor deprivation [31], and it was found to
localize to Lewy bodies and Lewy neurites [32]. Additionally, the
homologues of human FOXO1 have been recently involved in
Drosophila melanogaster or Caenorhabditis elegans models of PD, with
different post-translational modifications of the protein showing
either protective or harmful effects. Drosophila PINK1 null mutants
display mitochondrial dysfunction and dopaminergic neuron loss.
Koh et al. [33] showed that Sir2 (the homologue or the human
SIRT1/sirtuin 1 protein) and FOXO protect mitochondria and
dopaminergic neurons downstream of PINK1. Sir2 and SIRT1
Table 2. FoxO1 TFBS genes with evidence of partial mediation for the relationship between FOXO1 and PD.
Gene Probe Direct effect
1 Indirect effect
1
Ratio of indirect and
direct effects
% total effect
mediated p-value
ARMC3 A_23_P86540 0.63 0.68 1.09 52.1% 0.037
SMOX A_23_P102731 0.62 0.54 0.86 46.3% 0.032
NOTCH2 A_23_P200792 0.62 0.46 0.73 42.2% 0.030
CDKAL1 A_23_P73058 0.83 0.53 0.64 39.0% 0.035
PTPN13 A_23_P18493 0.77 0.46 0.59 37.2% 0.043
SLC27A1 A_23_P131111 0.84 0.48 0.57 36.3% 0.030
ZNF438 A_23_P161156 0.70 0.39 0.56 36.0% 0.026
PARD3 A_24_P35478 0.80 0.45 0.56 36.0% 0.040
KDSR A_32_P515088 0.72 0.40 0.55 35.5% 0.045
ANAPC16 A_32_P32207 0.77 0.42 0.54 35.2% 0.036
LGR4 A_24_P90216 0.74 0.38 0.52 34.2% 0.029
EIF4G3 A_23_P126241 0.72 0.36 0.50 33.5% 0.032
TOR1AIP2 A_24_P839239 0.78 0.38 0.49 33.0% 0.041
ERLIN1 A_23_P202029 0.85 0.42 0.49 33.0% 0.040
MAPRE1 A_24_P220058 0.79 0.37 0.46 31.6% 0.042
BCL2 A_23_P352266 0.78 0.36 0.46 31.4% 0.041
GLIS3 A_32_P39394 0.77 0.35 0.45 31.1% 0.037
EZR A_23_P19590 0.82 0.36 0.44 30.5% 0.048
INPPL1 A_23_P36322 0.84 0.36 0.42 29.8% 0.039
ZC3H12C A_23_P388993 0.83 0.35 0.42 29.6% 0.038
ELAVL1 A_23_P208477 0.79 0.33 0.41 29.2% 0.045
ATP6V0E1 A_23_P213840 0.86 0.34 0.39 28.1% 0.042
SOX2 A_23_P401055 0.83 0.32 0.39 27.9% 0.047
FZD7 A_23_P209449 0.94 0.35 0.37 27.0% 0.046
AGFG2 A_23_P311640 0.81 0.29 0.36 26.7% 0.046
AQP4 A_23_P107565 0.92 0.33 0.35 26.2% 0.043
SLITRK1 A_23_P37041 0.84 0.29 0.34 25.4% 0.047
NECAB3 A_23_P68628 0.90 0.29 0.32 24.4% 0.050
ACSS3 A_23_P339119 0.85 0.27 0.31 23.9% 0.048
1The direct effect represents the effect of FOXO1 expression on PD directly, while the indirect effect represents the effect that is mediated through each FoxO1 TFBS
gene.
doi:10.1371/journal.pgen.1002794.t002
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one of their targets. This protective effect was observed to take
place through overexpression of two FOXO target genes, SOD2
(superoxide dismutase 2, mitochondrial) and Thor. Kuwahara et al.
recently [34] studied the role of Serine-129 phosporylation of a-
synuclein in the transgenic C. elegans (Tg worm) model of
synucleinopathy. The pan-neuronal overexpression of nonpho-
sphorylatable (S129A) a-synuclein showed severe defects in the Tg
worm. Gene expression profiling of S129A-Tg worms showed
strong upregulation of Daf-16/FOXO pathway genes, which the
authors proposed to act against the dysfunction caused by the
S129A-a-synuclein. Two additional studies [35,36] reported that
phosporylation of FOXO at the same amino acid residue by the
LRRK2 (leucine-rich repeat kinase 2) protein or the PRKG2
(protein kinase, cGMP-dependent type II) protein in Drosophila
reduces dopaminergic neuron survival.
With our current study, we bring further evidence for the
importance of the FOXO1 gene in PD. In addition to the
differential expression of this gene in PD versus control BA9 and
SN tissue, an increased number of genes under the transcriptional
regulation of the FoxO1 transcription factor also have altered
expression in BA9 tissue in our study. Finally, SNPs in the FOXO1
region are associated with the age at onset for PD. The results of
our study warrant further investigation of the FOXO1 gene and of
its protein product in the pathogenesis of PD, and we consider the
exploration of the relationship between FOXO1, SMOX, and GAK
in various PD models as a possible follow-up step. Although we
presented multiple sources of evidence for the involvement of
FOXO1 in PD, we cannot rule out that the change in FOXO1
expression may be a secondary effect seen mainly in prefrontal
cortex and that this may not be primarily involved in the
pathogenesis of PD.
While FOXO1 represents our main finding, additional genes
with FDR-significant microarray probes and prior evidence for
involvement in PD analyses are worth mentioning. A few of these
genes are: HGF (hepatocyte growth factor, Entrez ID=3082),
which encodes a protein that promotes the survival and migration
of immature neurons [37,38], SLC41A1 (solute carrier family 41,
member 1, Entrez ID=254428), which was recently implicated in
PD genome-wide association and genotyping studies [39,40],
EGFR (epidermal growth factor receptor, Entrez ID=1956), a
gene shown to play a crucial role in the dopamine-induced
proliferation of adult neural precursor cells of subgranular,
subventricular, and subependymal zones [41,42], AQP4 (aqua-
porin 4, Entrez ID=361), which encodes for the predominant
aquaporin found in the brain, water channel involved in the
pathophysiology of cerebral disorders [43], and NEDD4 (neural
precursor cell expressed, developmentally down-regulated 4,
Entrez ID=4734), a gene that encodes for a ubiquitin ligase
involved in the endosomal-lysosomal pathway and ubiquitinates
alpha-synuclein [44]. These and other genes with prior evidence
for involvement in PD-related processes are promising targets for
further studies.
Finally, it is worthwhile to note the lack of overlap that we
observed between our study and the BA9 study performed by
Zhang et al. [11]. Some of the observed inconsistency may be due
to significant differences between these two microarray analyses.
For example, the different microarray platforms might assess
different transcripts for the considered genes, gender and disease
pathology might have a significant impact on the expression levels
of a large number of genes, and the different available sets of
covariates might affect the expression results (e.g. RIN is not
available for the Zhang et al. data). Even with this apparent lack of
overlap, we believe that transcriptome data are relevant and can
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PLoS Genetics | www.plosgenetics.org 7 June 2012 | Volume 8 | Issue 6 | e1002794help bring significant insights in the study of PD. A possible way to
alleviate incoherent results could be the establishment of standard
protocols for expression studies in brain samples, which is an
important, yet overlooked objective. Nonetheless, those findings
that do replicate, even with the existent microarray data (e.g.
FOXO1), may be pointing to important disease-related pathways.
Materials and Methods
Microarray samples
Brain tissue from the prefrontal cortex Brodmann Area 9 (BA9)
was obtained from three different brain banks: the Harvard Brain
Tissue Resource Center McLean Hospital, Belmont, Massachusetts,
the Human Brain and Spinal Fluid Resource Center VA, West Los
Angeles Healthcare Center, California, and the National Brain and
Tissue Resource for Parkinson’s Disease and Related Disorders at
Banner Sun Health Research Institute, Sun City, Arizona [45].
Thirty-three Parkinson disease (PD) and 29 control samples were
selectedforthemicroarraystudy.Thesampleswereselectedbasedon
the following criteria: (1) no significant Alzheimer disease pathology
(specified by neuropathology reports), (2) tissue pH.6.25, (3) similar
ages of death for PD cases and controls, and (4) male.
Microarray QC and differential expression analysis
Total RNA for the 33 PD and 29 control samples was extracted
with TRIzol (Invitrogen, Carlsbad, CA). RNA was purified using
the RNeasy MinElute Cleanup columns (Qiagen Sciences Inc,
Germantown, MD) and its quality was assessed with an Agilent
Bioanalyzer Nano Chip 2100 (Agilent, Foster City, CA). 1.65 mgo f
each RNA sample were labeled and hybridized to the One-Color
Agilent 60-mer Whole Human Genome Microarray (#G4112A) at
the Agilent Microarray Facility of the Whitehead Institute for
Biomedical Research (Cambridge, MA). The dye-normalized and
post surrogate processed signal for the green channel, gProcessed-
Signal, obtained from Agilent’s Feature Extraction Software was
used for downstream analyses. The raw expression data for the 62
samples were evaluated for individual array quality (MA plots),
array intensity distributions (box plots and density plots) and
between-array differences (heat maps representing the distance
between arrays) using the arrayQualityMetrics Bioconductor
package. Nine outlier samples were detected based on the
arrayQualityMetrics default criteria [46] and were dropped from
further analyses. Table 1 describes the retained microarray samples.
Post-mortem interval was the only significantly different covariate
between the retained cases and controls (p=0.02).
Microarray probes were removed if they had expression values
outside the detectable spike-in range in more than 50% of the
control arrays and more than 50% of the PD arrays, or if they had
any of the Agilent flags IsWellAboveBG=0, gIsSaturated=1,
gIsFeatPopnOL=1, gIsFeatNonUnifOL=1 in more than 75% of
the arrays. The median expression value was used for replicated
probes that passed the above filtering criteria. A total of 39,122
probes out of the total 45,015 probes present on the microarray
chips were analyzed in the expression and eSNP studies. The
expression data for the retained probes of the 53 arrays (E-MTAB-
812 ArrayExpress dataset) were quantile normalized, and the
obtained values were base 2 logarithm transformed. All the
microarray processing analyses were performed in R (http://www.
R-project.org), using the Agi4x44PreProcess and the limma
Bioconductor packages.
The relationship of PD/control status to probe expression levels
was determined using linear regression in R. The normalized and
log 2 transformed mRNA levels were modeled as the dependent
variable and the association of PD/control status was adjusted for
RNA integrity (RIN), post-mortem interval (PMI) and age at
death. The RIN and pH were the most highly correlated variables
in our data (Spearman correlation coefficient=0.403, p-val-
ue=0.001), and we decided to include in the linear regression
model only one of these two variables, to avoid the problem of
over-adjustment. We chose the RIN variable, given its larger
range of values compared with pH (Table 1). False discovery rate
(FDR) adjustment was applied to the obtained p-values for the
PD/control-probe expression relationship to account for multiple
comparisons.
DAVID analysis
The Agilent identifiers of the FDR significant probes were
uploaded and mapped to genes in the Database for Annotation,
Visualization and Integrated Discovery (DAVID v6.7, http://
david.abcc.ncifcrf.gov/, [47,48]) for functional annotation. All
available functional categories were considered, including Gen-
e_Ontology, Pathways, and Protein_Interactions (contains the
transcription factor binding site data from the UCSC database).
Ingenuity Pathway Analysis
The genes corresponding to FDR significant microarray probes
were analyzed through the use of Ingenuity Pathways Analysis
(Ingenuity Systems, www.ingenuity.com). A data set containing
FDR significant Agilent probe identifiers and corresponding fold
changes was uploaded into the application. Each identifier was
mapped to its corresponding gene in the Ingenuity Knowledge
Base. These genes were overlaid onto a molecular network
developed from information contained in the Ingenuity Knowl-
edge Base. A network of genes with involvement in neurological
diseases and processes was created (Figure S1).
Microarray validation experiment
The QuantiGene Plex 2.0 gene expression assay was used for
the validation of the microarray (Affymetrix, Santa Clara, CA).
The expression levels of 10 genes containing microarray probes
with FDR-adjusted p-values smaller than 0.05 (Table S3) and of
two control genes (TUBG1, tubulin, gamma 1; HPRT1, hypoxan-
thine phosphoribosyltransferase 1) were evaluated in a subset of 8
PD and 9 control samples from the Agilent microarray experiment
(Table S1). The QuantiGene probes designed by Affymetrix
targeted the exact transcripts as the ones targeted by the
considered Agilent probes (as defined by transcripts present in
the UCSC Genes, RefSeq Genes, and Ensembl Gene Predictions
tracks from the UCSC genome browser). Gene expression
measurements were performed in triplicates in lysed brain tissue,
without prior RNA extraction (the RIN covariate was not
available). To evaluate the gene expression differences between
the PD and control samples, the following procedure was used: 1)
for each gene expression measurement, the background value was
extracted from the raw expression count; 2) given the 3 different
background-extracted expression measurements for each gene, in
each sample, average expression values were calculated; 3) the
mean expression values for the ten genes were normalized by the
geometric mean of the two control genes in each sample; 4) the
base 2 logarithm of the obtained normalized values was calculated;
5) a linear model that included age and PMI was used to
determine the difference in expression between the two groups.
Analysis of prior PD prefrontal cortex and substantia
nigra microarray studies
The prefrontal cortex Brodmann Area 9 (BA9) microarray
expression data published by Zhang et al. [11] were used as a
FOXO1 Transcriptional Regulation in PD
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files for 14 PD and 16 control samples (Affymetrix Human Genome
U133A Array) and the corresponding annotation file were
downloaded from ArrayExpress (http://www.ebi.ac.uk/
arrayexpress/, E-GEOD-20168). The gcrma method was used to
background correct, normalize, and summarize probes for the 30
brain samples. The obtained normalized and base 2 logarithm
transformed expression values for the 22,283 available probes were
modeled as the dependent variable and the association of PD/
control status was adjusted for sex, age at death, PMI, and pH. One
control sample lacked covariate information and was removed
(GSM506036_1134_BA9_Cm.CEL). After adjustment for covari-
ates, none of the analyzed probes reached FDR significance. To
compare our Agilent microarray results with the Zhang et al.
Affymetrixresults, weannotatedtheprobesforthe two microarrays,
and assigned the probe with the best p-value to each gene. For the
Affymetrix data, 17,564 of the available probes could be assigned to
11,441 Entrez identifiers, while for the Agilent data, 29,927 probes
could be assigned to 20,474 Entrez identifiers. There were 11,191
Entrez identifiers common for the two microarrays, and we used a
x
2 test to evaluate if the overlap between the top genes observed in
the two microarrays was larger than expected by chance. For the
purpose of the x
2 test, we defined the top genes as the set of FDR
significant genes (FDR adjusted p-value,0.05) for our Agilent
microarray [278 genes with Entrez IDs and in common with the
Affymetrix array], and the set of genes with unadjusted p-values
smaller than 0.05 for the smaller Affymetrix microarray [1,012
genes with Entrez IDs and in common with the Agilent array]. The
overlap between these two sets of genes consisted of 27 genes, which
are highlighted in Table S2.
Additional Affymetrix PD expression studies performed in the
substantia nigra (SN) brain region and present in the ArrayExpress
or in the National Brain Databank (NBR, http://
national_databank.mclean.harvard.edu/brainbank/Main) public
repositories were analyzed similarly to the Zhang et al. data.
Since the available covariates for each of the studies varied, we
present the results obtained when 1) no covariate was added to the
used linear model, and 2) the covariates age or sex (depending on
availability) were included. Only the expression studies containing
at least one of the two FOXO1 probes present in the BA9
Affymetrix study, 202723_s_at and 202724_s_at, were considered
(Table S4). This includes PD studies performed on the following
Affymetrix chips: HG-U133A, HG-U133_Plus_2, and HG-Focus
(E-GEOD-8397, E-GEOD-20163, E-GEOD-20164, E-GEOD-
20186, E-GEOD-20295, E-GEOD-7621, E-GEOD-20141, E-
GEOD-20333, and the Simunovic et al. PD study [10] present in
NBR). We meta-analyzed the results obtained using 1) no
covariates and 2) the covariates age or sex (depending on
availability) for the 3 FOXO1 probes included in all or part of
the 9 studies using the weighted Z-score approach [49]. This
method was chosen since it takes into account both the direction of
association and the sample size of the individual studies. The Z-
scores for the microarray probes of each expression study were
obtained from p-values using the standard normal distribution.
This conversion was performed in R by using the function
qnorm(p-value/2) and changing the sign of the Z-statistic to match
the direction of the estimate of association.
Mediation analysis
A mediation analysis was performed to assess whether or not the
observed association between PD and FOXO1 expression acted
through a pathway containing any of the FDR significant FoxO1
TFBS genes. Mediation is assessed by a multistep analysis [50], in
which the total effect of FOXO1 is broken down into a direct effect
and an indirect effect, acting through the intervening gene. The three
analysis steps were: 1) in order to decompose the effects, a logistic
regression was performed with PD as the dependent variable and the
more strongly associated FOXO1 probe (A_23_P151426) as the
predictor to establish the total effect (in the original microarray
analysis, expression was used as the dependent variable); 2) a linear
regression was performed to establish association between FOXO1
expression and the expression of each of the PD-associated FoxO1
TFBS genes; 3) a logistic regression was performed using each of the
FoxO1 TFBS genes as a predictor of PD including FOXO1expression
in the model. All regressions were adjusted for age, PMI, and RIN.
The direct effect is determined from the beta estimate of FOXO1 in
step 3 of the analysis, while the indirect effect is the product of the
beta estimates for the relation between FOXO1 and the FoxO1 TFBS
gene and the relation between the TFBS gene and PD after
standardization of the betas to account for combination of linear and
logistic regressions [51]. Finally, the null hypothesis that the indirect
effect equals zero is tested using a Z test [52]. The results are
displayed in Table 2.
SNP genotyping
The 53 retained microarray samples were included among 5,849
PD cases and controls genotyped in the US PD-GWAS consortium
meta-analysis replication sample [8]. The samples were genotyped
using a custom Illumina genotyping array of 768 SNPs, and 56
SNPs provided genome-wide level of significance in the combined
discoveryand replicationphases,andwereconsideredforfunctional
eSNP analyses of the microarray data. Three of the microarray
brain samples failed to genotype at the accepted 98% success rate
and were removed from the eSNP analysis.
eSNP analysis
We performed a targeted trans-effect eSNP analysis in the
microarray brain samples for: 1) 52 of the 56 genome-wide
significant SNPs from the US PD-GWAS consortium study with
minor allele frequencies (MAF) of at least 0.1, and 2) a set of 189
microarray probes with FDR-adjusted p-values,0.05 and which
mapped to genes with FoxO1 TFBS (Table S2). Many of the
genome-wide significant SNPs in the PD associated regions were
in strong to moderate linkage disequilibrium (LD); therefore, we
used the program SimpleM [53] to determine the effective number
of SNPs tested after accounting for LD in each of the different
regions to be N=34. A modified Bonferroni correction method
[54] was used to calculate the required eSNP p-value for a 0.05
alpha level as 5.36E-5. Association between the SNPs and probe
expression levels was evaluated in the 26 cases and 24 controls
using a 2-degree of freedom (df) linear regression model
implemented in Plink [55]. The 2-df model permits a simultaneous
test of association between genotype and expression and between
genotype and difference in association between cases and controls.
This method has been used previously for eQTL studies involving
mixed case and control samples and increases the power to detect
effects of SNPs on expression levels that may be unique to disease
[56]. In addition to including SNP, case status and the SNP x case
status interaction term, the linear models were adjusted for RNA
integrity number (RIN), post-mortem interval (PMI), and age at
death. All SNPs were coded using a dominant model.
PD affection and age at onset meta-analysis for the
FOXO1 gene region
We considered the region on chromosome 13 covering the FOXO1
g e n e ,a sw e l la st h ea r e a su pt o1M ba w a yf r o mt h e3 9 and 59 ends of
the gene (chr13: 39,027,801–41,138,734, hg18). In this region, there
FOXO1 Transcriptional Regulation in PD
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analysis of PD affection. Using the SimpleM program [53] and the
imputed data for the NGRC GWAS,the largeststudy included in the
meta-analysis, we determined the corresponding number of effective
SNPs in the FOXO1 region to be N=576. Since SimpleM uses only
genotype data, each SNP wasassigned the imputed genotype with the
highest confidence for the purpose of this analysis. Given this number
of effective SNPs, a p-value of 8.68E-5 was required for an alpha level
of 0.05. In addition to the PD risk meta-analysis conducted by the US
PD-GWAS consortium [8], a meta-analysis of age at onset of PD was
conducted in 6 PD GWAS studies: the five studies present in the US
PD-GWAS consortium (PROGENI/GenePD, NIA Phase I, NIA
Phase II, HIHG, NGRC) and the LEAPS study [57]. Prior to meta-
analysis, results were filtered for imputation efficiency and any study
with a MACH-derived Rsq,0.30 did not contribute a result for that
SNP to the meta-analysis. Meta-analysis was performed with
METAL ([49], http://www.sph.umich.edu/csg/abecasis/Metal/)
using an inverse-variance weighting scheme. This allowed an overall
effect size to be estimated. Genomic control was employed so that
results were down-weighted if the study’s lambda exceeded 1.00.
Supporting Information
Figure S1 IPA generated network enriched in neurologically
involved genes. All displayed genes contain at least an FDR-
significant probe in the Agilent microarray study. Up-regulation in
PD compared to control samples is represented with red color, and
down-regulation with green color. The genes depicted as ovals
contain FoxO1 transcription factor binding sites, while the genes
depicted as triangles do not. Solid lines correspond to direct
interactions, and dashed lines to indirect interactions.
(TIF)
Table S1 Full description of microarray sample.
(DOC)
Table S2 Agilent microarray FDR-significant probes.
1The
probe and gene names corresponding to genes with FoxO1 TFBS
are displayed in bold. The probes that do not reach FDR-level of
significance when the 3 samples with RIN,6 are dropped from
the differential expression analysis are highlighted in red.
2The p-
values of the genes that had at least one probe with nominal
significance (p,0.05) in the Zhang et al. study are displayed in
bold.
(XLSX)
Table S3 Validation study results.
(DOC)
Table S4 FOXO1 probe expression results for all Affymetrix
substantia nigra PD microarrays available in the Array Express and
National Brain Databank repositories
1.
(DOC)
Table S5 Agilent microarray FDR-significant probes after
removal of low RIN samples.
1The probe and gene names
corresponding to genes with FoxO1 TFBS are displayed in bold.
(XLSX)
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